|
US20060167241A1
(en)
*
|
2003-07-15 |
2006-07-27 |
Mitsui Chemicals, Inc. |
Method for synthesizing cyclic bisdinucleoside
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
DK2559690T3
(en)
|
2005-05-10 |
2016-04-25 |
Incyte Holdings Corp |
Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
US20080125470A1
(en)
|
2006-09-19 |
2008-05-29 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CA2932121A1
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics Corporation |
Ido inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
CN103951753B
(zh)
|
2009-09-03 |
2018-01-12 |
默沙东公司 |
抗‑gitr抗体
|
|
ES2601226T3
(es)
|
2009-10-28 |
2017-02-14 |
Newlink Genetics Corporation |
Derivados de imidazol como inhibidores de IDO
|
|
CN105218672A
(zh)
|
2009-12-10 |
2016-01-06 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
|
ME03447B
(me)
|
2010-03-04 |
2020-01-20 |
Macrogenics Inc |
Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 csf-1r에 대한 항체 및 이의 용도
|
|
RU2617966C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
KR20200044999A
(ko)
|
2010-05-04 |
2020-04-29 |
파이브 프라임 테라퓨틱스, 인크. |
Csf1r에 결합하는 항체들
|
|
CN105481983B
(zh)
|
2010-09-09 |
2021-09-03 |
辉瑞公司 |
4-1bb结合分子
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
JP6416630B2
(ja)
|
2012-02-06 |
2018-10-31 |
ジェネンテック, インコーポレイテッド |
Csf1r阻害剤を用いるための組成物及び方法
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
HRP20191754T1
(hr)
*
|
2012-04-17 |
2020-01-24 |
Gilead Sciences, Inc. |
Spojevi i postupci za antivirusno liječenje
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
WO2013181634A2
(en)
|
2012-05-31 |
2013-12-05 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind pd-l1
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
TWI713436B
(zh)
|
2012-08-31 |
2020-12-21 |
美商戊瑞治療有限公司 |
用結合群落刺激因子1受體(csf1r)之抗體治療病狀之方法
|
|
WO2014099824A1
(en)
*
|
2012-12-19 |
2014-06-26 |
Board Of Regents, The University Of Texas System |
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−1(pd−1)に対する抗体
|
|
CN105188373B
(zh)
|
2013-05-18 |
2017-09-22 |
艾杜罗生物科技公司 |
抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法
|
|
US9549944B2
(en)
*
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
CA2913977C
(en)
|
2013-05-31 |
2022-11-29 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
HRP20221262T1
(hr)
|
2013-09-13 |
2022-12-09 |
Beigene Switzerland Gmbh |
Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
|
|
SI3081576T1
(sl)
|
2013-12-12 |
2019-12-31 |
Shanghai Hengrui Pharmaceutical Co., Ltd., |
Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
CN107148424B
(zh)
*
|
2014-12-16 |
2021-01-08 |
凯拉治疗股份公司 |
用于诱导细胞因子的环状二核苷酸
|
|
SG11201707383PA
(en)
|
2015-03-13 |
2017-10-30 |
Cytomx Therapeutics Inc |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
BR112018002757A8
(pt)
|
2015-08-13 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
|
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
|
AU2017378782A1
(en)
|
2016-12-20 |
2019-07-04 |
Merck Sharp & Dohme Corp. |
Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
US20200113924A1
(en)
|
2016-12-20 |
2020-04-16 |
Merck Sharp & Dohme Corp. |
Cyclic dinucleotide sting agonists for cancer treatment
|